Compare ORC & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ORC | NTLA |
|---|---|---|
| Founded | 2010 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 986.9M |
| IPO Year | 2013 | 2016 |
| Metric | ORC | NTLA |
|---|---|---|
| Price | $8.06 | $13.27 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 19 |
| Target Price | $7.50 | ★ $17.32 |
| AVG Volume (30 Days) | ★ 6.8M | 4.8M |
| Earning Date | 01-29-2026 | 02-26-2026 |
| Dividend Yield | ★ 17.65% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.57 | N/A |
| Revenue | ★ $80,187,000.00 | $57,528,000.00 |
| Revenue This Year | $90.64 | $1.96 |
| Revenue Next Year | $78.88 | N/A |
| P/E Ratio | $14.22 | ★ N/A |
| Revenue Growth | 5.93 | ★ 33.52 |
| 52 Week Low | $5.69 | $5.90 |
| 52 Week High | $9.01 | $28.25 |
| Indicator | ORC | NTLA |
|---|---|---|
| Relative Strength Index (RSI) | 68.00 | 76.79 |
| Support Level | $7.73 | $11.34 |
| Resistance Level | $8.34 | $9.62 |
| Average True Range (ATR) | 0.18 | 0.85 |
| MACD | 0.07 | 0.41 |
| Stochastic Oscillator | 76.47 | 80.45 |
Orchid Island Capital Inc is a specialty finance company that invests in residential mortgage-backed securities. The principal and interest payments of its RMBS are guaranteed by the Federal National Mortgage Association, the Federal Home Loan Mortgage Corporation, or the Government National Mortgage Association, and are backed by single-family residential mortgage loans. The company's investment portfolio is divided into two categories namely traditional pass-through Agency RMBS; and structured Agency RMBS, such as collateralized mortgage obligations, interest-only securities, inverse interest-only securities, and principal-only securities, among other types of structured Agency RMBS.
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.